| pubmed-article:7538257 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0011615 | lld:lifeskim |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0445550 | lld:lifeskim |
| pubmed-article:7538257 | lifeskim:mentions | umls-concept:C0439536 | lld:lifeskim |
| pubmed-article:7538257 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7538257 | pubmed:dateCreated | 1995-6-9 | lld:pubmed |
| pubmed-article:7538257 | pubmed:abstractText | Twenty-two patients with severe atopic eczema were included in a therapy study with UV-A1 (wavelengths > 340 nm) treatment. The patients were divided into two dose groups, each consisting of 11 patients. One group received 10 J/cm2 and the other 50 J/cm2 five times a week for 3 consecutive weeks. No topical or systemical steroids or antihistamines were allowed. Using the SCORAD index as a measure of disease activity before onset of therapy and after 10 and 15 treatments, we observed a significant improvement in both dose groups after 15 treatments (10 J/cm2: p < 0.05, 50 J/cm2: p < 0.005). After 10 treatments only the improvement in the 50 J/cm2 group was significant (p < 0.005); the difference between the two dose groups was significant (p < 0.05). The clinical efficacy of treatment was reflected neither by a decrease of serum IgE nor by a decrease of elevated serum levels of soluble adhesion molecules sICAM-1 and sELAM-1 in the two dose groups. In contrast, a marked but not significant decrease of serum ECP could be observed in the 50 J/cm2 group only. We conclude from these and other published data that although 10 J/cm2 UV-A1 has a limited effect on patients with severe atopic eczema, higher doses are of higher efficiency in the treatment of this condition. | lld:pubmed |
| pubmed-article:7538257 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7538257 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7538257 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7538257 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7538257 | pubmed:issn | 0001-5555 | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:RingJJ | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:KöhlerII | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:NeuberKK | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:WeichenthalMM | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:KowalzickLL | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:KleinheinzAA | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:GroschJJ | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:LungwitzGG | lld:pubmed |
| pubmed-article:7538257 | pubmed:author | pubmed-author:SeegebergCC | lld:pubmed |
| pubmed-article:7538257 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7538257 | pubmed:volume | 75 | lld:pubmed |
| pubmed-article:7538257 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7538257 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7538257 | pubmed:pagination | 43-5 | lld:pubmed |
| pubmed-article:7538257 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:meshHeading | pubmed-meshheading:7538257-... | lld:pubmed |
| pubmed-article:7538257 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7538257 | pubmed:articleTitle | Low dose versus medium dose UV-A1 treatment in severe atopic eczema. | lld:pubmed |
| pubmed-article:7538257 | pubmed:affiliation | Department of Dermatology, University of Hamburg, Germany. | lld:pubmed |
| pubmed-article:7538257 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7538257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7538257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7538257 | lld:pubmed |
